Express News | InnoCare Announces Clearance of Clinical Trial of Tyk2 Inhibitor Icp-332 by U.S. FDA
Innocare (09969) anti-CD19 monoclonal antibody is expected to be included in priority review for the treatment of this type of blood cancer.
Innocare (09969) has applied for priority review of injection of Tafasitamab.
InnoCare Pharma CEO Boosts Shareholding to 7.16%
InnoCare Pharma (HKG:9969, SHA:688428) Chief Executive Officer Jisong Cui purchased 316,000 shares in the company, bringing her family's aggregate shareholding to 7.16%, according to a Friday filing w
InnoCare Pharma Grants Over 1.7 Million Shares Under Incentive Scheme
InnoCare Pharma (HKG:9969) granted 1,737,000 restricted shares to 47 employees under a share award scheme at 6.95 yuan each, according to a Thursday filing with the Hong Kong Stock Exchange. The compa
InnoCare CEO Buys Shares, Signals Confidence
Nuocheng Jianhua (09969.HK) received 316,000 shares from CEO and Executive Director Cui Jisong
Gelonghui, May 31, 丨 Nuocheng Jianhua (09969.HK) issued an announcement. Dr. Cui Jisong, CEO and executive director of the company, informed the company that he used personal funds to purchase a total of 316,000 shares in the open market on May 30, 2024. After the increase in shares, Dr. Cui and his family's total shares in the company accounted for about 7.16% of the total number of shares issued by the company as of the date of this announcement. Dr. Choi said that the increase in shares reflects full confidence in the company's pipeline product development and the company's commercialization prospects and growth potential. Dr. Choi does not rule out the possibility of further increasing the company's shares at the right time
InnoCare Pharma Awards Shares to Incentivize Staff
Nuocheng Jianhua (688428.SH) grants 1.777 million restricted shares at a grant price of 6.95 yuan/share
Nuocheng Jianhua (688428.SH) announced that the company's “2023 Science and Technology Innovation Board Restricted Stock Incentive Plan (Draft...
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Changes in Hong Kong stocks | Nuochengjianhua (09969) is now up more than 4%. ICP-488 completes phase II clinical trial for psoriasis, patients enrolled
The Zhitong Finance App learned that Nuocheng Jianhua (09969) is now up more than 4%. As of press release, it has risen 4.41% to HK$5.21, with a turnover of HK$11.394,400. According to the news, on May 16, Nuochengjianhua announced that the phase II clinical trial of the TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor ICP-488 developed independently by the company to treat psoriasis has completed patient enrollment. ICP-488 showed good efficacy and safety in a phase I study in treating patients with psoriasis. Furthermore, Goldman Sachs released a research report saying that Nuochengjianhua's sales were weak in the first quarter, and its obutinib sales were 1
Goldman Sachs: Target price raised to HK$8.6 for Nuochengjianhua's “buy” rating
Goldman Sachs released a research report stating that it gave Nuocheng Jianhua (09969) a “buy” rating, raised the company's sales forecast for the full year of this year from RMB 817 million to RMB 839 million, and lowered the profit estimates for each year from 2024 to 2026. The target price rose slightly from HK$8.58 to HK$8.6. According to the report, the company's sales were weak in the first quarter. Its sales of Orelabrutinib (Orelabrutinib) were 165 million yuan, up 9% year over year and down 13% from quarter to quarter. Recovery was slower than expected because new indications for treating relapsed/refractory marginal zone lymphoma (MZL) were included
InnoCare Pharma Concludes Subject Enrolment Phase II Psoriasis Trial
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
Innocare Pharma Posts Q1 Loss
Innocare Pharma (HKG:9969) posted a loss attributable to shareholders of 142.4 million yuan, or 0.08 yuan per share, for the first quarter, according to a Monday filing with the Hong Kong Exchange. Op
Nuochengjianhua Pharmaceutical Co., Ltd. report for the first quarter of 2024
Gelonghui Announcement Selection (Hong Kong Stock) | Tencent Music - SW (01698.HK) Net profit from the first quarter increased 23.9% year-on-year, and the net increase in the number of online music paying users reached a record high
[Today's Focus] Tencent Music-SW (01698.HK)'s net profit for the first quarter increased 23.9% year-on-year, and the net increase in the number of online music paying users reached a record high. Tencent Music-SW (01698.HK) announced unaudited financial results for the first quarter of 2024. In the first quarter of 2024, total revenue was RMB 6.77 billion (US$937 million), down 3.4% year on year; online music subscription revenue was RMB 3.62 billion (US$501 million), up 39.2% year over year. The number of online music paying users increased 20.2% year over year to 113.5 million.
InnoCare Logs Loss in Q1
InnoCare (SHA:688428, HKG:9969) recorded an attributable loss of 142.4 million yuan for the first quarter of 2024, a Monday filing on the Hong Kong bourse said. Diluted loss per share for the three mo
Nuochengjianhua (09969.HK) R&D investment increased 26.09% in the first quarter, gross margin rose to 85.4%, holding about 8.2 billion yuan in monetary capital
Gelonghui, May 13 | Nuocheng Jianhua (09969.HK) announced that it achieved a total operating revenue of RMB 166 million from January to March 2024. At the same time, the company continued to raise its gross profit level. The gross margin for January-March 2024 was 85.4%, an increase of 8.1 percentage points over 77.3% in the same period last year. The total R&D investment during this period was 178 million yuan, an increase of 26.09% over the previous year. Sales revenue of the company's core product, obutinib (INOC), continued to grow. From January to March 2024, sales revenue totaled RMB 164 million, an increase of 9% over the previous year. Entering 2024, accompanied by
Nuochengjianhua (688428.SH) announced first-quarter results with a net loss of 142 million yuan
Nuocheng Jianhua (688428.SH) released its report for the first quarter of 2024. The company's revenue was 166 million yuan...
諾誠健華:2024年第一季度季度報告
No Data